Logo

Dragonfly and Celgene Extended their Collaboration from 2017- for the Treatment of Solid and Hematological Cancers

Share this
Dragonfly and Celgene Extended their Collaboration from 2017- for the Treatment of Solid and Hematological Cancers

Dragonfly and Celgene Extended their Collaboration from 2017- for the Treatment of Solid and Hematological Cancers

Shots:
  • Celgene has added four more immunotherapies (making it eight- to 2017 deal) to develop and commercialize with an option to license WW IPR of the developed product- using Dragonfly’s TriNKET technology
  • Dragonfly to get $50M upfront with milestones and royalties (if the option to license is exercised by Celgene)
  • TriNKET technology (Tri-specific- NK cell Engager Therapeutics) uses NK cells- for developing immunotherapies for cancer
Ref: PRNewsWire| Image:  The Street
Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions